Dynamic Stabilometry Combined With Transcranial Direct Current Stimulation for Balance and Motor Recovery After Ischemic Stroke (STAB-tDCS)
Efficacy of Combined Dynamic Stabilometry and Transcranial Electrical Stimulation in the Early Recovery Period of Ischemic Stroke in Patients With Hemiparesis: a Single-Center Randomized Study
The goal of this clinical trial is to learn if balance training on a moving (dynamic) platform with visual and sound feedback, combined with weak electrical brain stimulation, helps people recover balance and movement after an ischemic stroke with weakness on one side of the body (hemiparesis).
The main questions it aims to answer are:
- Does the combination of dynamic platform training and active brain stimulation improve balance more than either method alone?
- Does it improve independence in daily activities, mobility and walking, and reduce fall risk?
- Is the combined treatment safe in the early period after stroke? Researchers will compare four groups: dynamic platform training with active stimulation, dynamic platform training with sham (imitation) stimulation, training on a locked (static) platform with active stimulation, and training on a locked platform with sham stimulation.
Participants will:
- Receive standard rehabilitation (exercise therapy and physiotherapy) of the same volume in all groups.
- Complete 10 sessions of 20-minute platform training over 12 days (5 sessions per week), with active or sham brain stimulation during each session.
- Have balance, mobility and neurological tests on Day 0, Day 6 and Day 12.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Background and Rationale. Stroke is a leading cause of long-term disability. Motor impairment, primarily hemiparesis, occurs in 60-80% of stroke survivors and limits functional independence and quality of life. The early recovery period (7-30 days after stroke onset) is characterized by enhanced neuroplasticity and is considered an optimal window for intensive rehabilitation.
Dynamic stabilometry with biofeedback is active postural control training: the patient receives real-time visual and auditory information on the position of the center of pressure while balancing on a moving platform. Unlike static stabilometry, the dynamic mode creates a controlled sensory load on the postural system and engages adaptive cerebellar-cortical mechanisms. Anodal transcranial direct current stimulation (tDCS) over the primary motor cortex (M1) increases cortical excitability and may potentiate motor learning. tDCS combined with active motor training has shown synergistic effects, but its combination with dynamic stabilometry has not been studied.
Interventions. Dynamic stabilometry is performed on the ReviStabix stabilometric trainer (Samara State Medical University; Russian medical device registration No. G004-00110-00/03075665 of August 29, 2025) in dynamic mode with visual and auditory biofeedback, at a fixed standard platform angle. In the control condition the platform is locked (static mode). tDCS is delivered with the Neurostim device (Neurosoft, Russia; registration certificate No. RZN 2021/13529 of February 20, 2021): anodal stimulation, 2 mA, electrode area 35 cm², 20 minutes; anode over M1, cathode over the supraorbital area. Stimulation starts simultaneously with the stabilometry session. Sham tDCS uses the same electrode montage; current is delivered for the first 30 seconds and then switched off automatically.
Study Design and Participant Groups. This is a prospective, single-center, pilot randomized controlled trial with a 2×2 factorial design (dynamic vs static stabilometry × active vs sham tDCS). A total of 120 patients aged 30-85 years with ischemic stroke and mild to moderate hemiparesis will be randomized 1:1:1:1 into four groups of 30: (A) dynamic stabilometry + active tDCS; (B) dynamic stabilometry + sham tDCS; (C) static stabilometry + active tDCS; (D) static stabilometry + sham tDCS. Randomization is in blocks of 8, stratified by age (<65 / ≥65 years) and side of the lesion (left / right hemisphere), with allocation concealment by sealed opaque envelopes or centralized web-based randomization. Participants are blinded to the type of stimulation (active / sham), and outcome assessors are blinded to group allocation.
What Participation Involves. All groups receive standard rehabilitation of equal volume (exercise therapy, physiotherapy), recorded in a session log. The study course consists of 10 sessions of 20 minutes over 12 days (5 sessions per week on weekdays). Assessments are performed at baseline (Day 0), Day 6 and Day 12: Berg Balance Scale (primary outcome), Functional Independence Measure, Morse Fall Scale, Hauser Ambulation Index, modified Rankin Scale, Rivermead Mobility Index, National Institutes of Health Stroke Scale, Medical Research Council muscle strength scale and Modified Ashworth Scale. Adverse events are recorded throughout the course.
Statistical Analysis. The primary analysis is ANCOVA of Day 12 BBS adjusted for baseline BBS, in the intention-to-treat population. Mixed ANOVA is used for changes across Day 0, 6 and 12, and 2×2 factorial ANOVA to test the interaction (dynamic stabilometry × tDCS). Effect sizes are expressed as Cohen's d; α = 0.05, power 80%. Sample size assumes an expected BBS difference of 6 points (SD 10, d = 0.6).
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前：Alexander Zakharov, MD
- 電話番号：+79171620301
- メール：a.v.zaharov@samsmu.ru
研究連絡先のバックアップ
- 名前：Yulia Minina, MD
- 電話番号：+79171195502
研究場所
-
-
Russia
-
Samara、Russia、ロシア、443095
- Samara City Clinical Hospital No. 2 named after N.A. Semashko
-
コンタクト：
- Alexander Zakharov
- 電話番号：+79171620301
- メール：a.v.zaharov@samsmu.ru
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Ischemic stroke verified by neuroimaging (computed tomography or magnetic resonance imaging)
- Mild or moderate hemiparesis
- Time since stroke onset from 7 days to 6 months
- Ability to stand with support for at least 30 seconds
- Age 30 to 85 years
- Mini-Mental State Examination (MMSE) score ≥ 20
- Medical stability (no acute somatic complications)
- Signed informed consent
Exclusion Criteria:
- Hemorrhagic stroke
- History of epilepsy or seizures
- Intracranial metal implants or cardiac pacemaker
- Severe aphasia preventing understanding of instructions
- Marked vestibular dysfunction (Meniere's disease, benign paroxysmal positional vertigo in exacerbation)
- Severe visual impairment preventing use of visual biofeedback
- Severe lower limb spasticity (Modified Ashworth Scale ≥ 3)
- Severe concomitant orthopedic disorders preventing verticalization
- Unstable somatic condition (heart failure NYHA class III-IV, unstable angina, blood pressure > 180/110 mm Hg)
- Recurrent stroke within the last 3 months
- MMSE score < 20
- Scalp diseases in the electrode placement areas
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：階乗代入
- マスキング：ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的：Experimental Arm A: Dynamic stabilometry + Active tDCS
Standard rehabilitation plus dynamic stabilometry with visual and auditory biofeedback (20 min) synchronized with active anodal tDCS over M1 (2 mA, 20 min); 10 sessions, 5 times/week, over 12 days. |
Active balance training on a stabilometric platform in dynamic mode with real-time visual and auditory feedback on the center of pressure; fixed standard platform angle; 20-min sessions. Anodal transcranial direct current stimulation, 2 mA, electrode area 35 cm², 20 min; anode over M1, cathode over the supraorbital area; starts simultaneously with the stabilometry session. Exercise therapy and physiotherapy of equal volume in all groups, recorded in a session log. |
|
アクティブコンパレータ：Control Arm B: Dynamic stabilometry + Sham tDCS
Standard rehabilitation plus dynamic stabilometry with biofeedback (20 min) with sham tDCS (current for the first 30 s only); 10 sessions, 5 times/week, over 12 days. |
Active balance training on a stabilometric platform in dynamic mode with real-time visual and auditory feedback on the center of pressure; fixed standard platform angle; 20-min sessions. Exercise therapy and physiotherapy of equal volume in all groups, recorded in a session log. Same electrode montage as active tDCS; current delivered for the first 30 s to mimic skin sensations, then switched off automatically. |
|
アクティブコンパレータ：Control Arm C: Static stabilometry + Active tDCS
Standard rehabilitation plus training on the locked (static) platform (20 min) synchronized with active anodal tDCS over M1 (2 mA, 20 min); 10 sessions, 5 times/week, over 12 days. |
Anodal transcranial direct current stimulation, 2 mA, electrode area 35 cm², 20 min; anode over M1, cathode over the supraorbital area; starts simultaneously with the stabilometry session. Exercise therapy and physiotherapy of equal volume in all groups, recorded in a session log. Training on the same stabilometric platform with the platform locked (static mode), same session duration; controls for the dynamic platform component. |
|
偽コンパレータ：Control Arm D: Static stabilometry + Sham tDCS
Standard rehabilitation plus training on the locked (static) platform (20 min) with sham tDCS; 10 sessions, 5 times/week, over 12 days. |
Exercise therapy and physiotherapy of equal volume in all groups, recorded in a session log. Same electrode montage as active tDCS; current delivered for the first 30 s to mimic skin sensations, then switched off automatically. Training on the same stabilometric platform with the platform locked (static mode), same session duration; controls for the dynamic platform component. |
この研究は何を測定していますか？
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline in Berg Balance Scale (BBS)
時間枠：Baseline (Day 0) and Day 12
|
The BBS assesses static and dynamic balance with 14 items; total score ranges from 0 to 56, where higher scores indicate better balance. |
Baseline (Day 0) and Day 12
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline in Berg Balance Scale (BBS) at Day 6
時間枠：Baseline (Day 0) and Day 6
|
Interim BBS assessment; range 0 to 56, where higher scores indicate better balance. |
Baseline (Day 0) and Day 6
|
|
Change from Baseline in Functional Independence Measure (FIM)
時間枠：Day 0, Day 6, Day 12
|
The FIM assesses the level of assistance needed in daily activities (motor and cognitive domains); total score ranges from 18 to 126, where higher scores indicate greater independence. |
Day 0, Day 6, Day 12
|
|
Change from Baseline in Morse Fall Scale (MFS)
時間枠：Day 0, Day 6, Day 12
|
The MFS estimates fall risk from six items; score ranges from 0 to 125, where higher scores indicate higher fall risk. |
Day 0, Day 6, Day 12
|
|
Change from Baseline in Hauser Ambulation Index (HAI)
時間枠：Day 0, Day 6, Day 12
|
The HAI rates walking ability from 0 (fully active) to 9 (restricted to wheelchair, unable to transfer), where higher scores indicate worse mobility. |
Day 0, Day 6, Day 12
|
|
Change from Baseline in modified Rankin Scale (mRS)
時間枠：Day 0, Day 6, Day 12
|
The mRS measures global disability and dependence; range 0 (no symptoms) to 6 (death), where higher scores indicate greater disability. |
Day 0, Day 6, Day 12
|
|
Change from Baseline in Rivermead Mobility Index (RMI)
時間枠：Day 0, Day 6, Day 12
|
The RMI assesses functional mobility with 15 items from turning in bed to running; range 0 to 15, where higher scores indicate better mobility. |
Day 0, Day 6, Day 12
|
|
Change from Baseline in National Institutes of Health Stroke Scale (NIHSS)
時間枠：Day 0, Day 6, Day 12
|
The NIHSS quantifies stroke-related neurological deficit; range 0 to 42, where higher scores indicate more severe deficit. |
Day 0, Day 6, Day 12
|
|
Change from Baseline in Medical Research Council (MRC) Muscle Strength Score
時間枠：Day 0, Day 6, Day 12
|
Muscle strength of the paretic limbs graded per muscle group from 0 (no contraction) to 5 (normal strength), where higher scores indicate greater strength. |
Day 0, Day 6, Day 12
|
|
Change from Baseline in Modified Ashworth Scale (MAS)
時間枠：Day 0, Day 6, Day 12
|
The MAS measures resistance to passive movement (spasticity) from 0 to 4, where higher scores indicate more severe spasticity. |
Day 0, Day 6, Day 12
|
|
Number of Participants With Adverse Events
時間枠：Day 0 through Day 12
|
Adverse events related to stabilometry or tDCS (e.g., skin irritation, headache, dizziness, falls, seizures), recorded at each session. |
Day 0 through Day 12
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- SamSMU-BEC-322-2026
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Anonymized individual participant data underlying the published results (baseline characteristics and outcome scores).
IPD 共有時間枠
Beginning at publication of the main results, available for 5 years
IPD 共有アクセス基準
Available as supporting information with the journal article; other requests to the Principal Investigator with a methodologically sound proposal
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。